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Obesity-dependent changes in interstitial  ECM mechanics promote 
breast tumorigenesis 
Bo Ri Seo,1 Priya Bhardwaj,2 Siyoung Choi,1 Jacqueline Gonzalez,1 Roberto C. Andresen Eguiluz,3 Karin 
Wang,1,3 Sunish Mohanan,4 Patrick G. Morris,5 Baoheng Du,2 Xi K. Zhou,6 Linda T. Vahdat,2 Akanksha 
Verma,7 Olivier Elemento,7 Clifford A. Hudis,5 Rebecca M. Williams,1 
Delphine Gourdon,3 Andrew J. Dannenberg,2 Claudia Fischbach1,8* 
Obesity and extracellular matrix (ECM) density are considered independent risk and prognostic factors for breast cancer. 
Whether they are functionally linked is uncertain. We investigated the hypothesis that obesity enhances local myofibroblast 
content in mammary adipose tissue and that these stromal changes increase malignant potential by enhancing interstitial ECM 
stiffness. Indeed, mammary fat of both diet- and genetically induced mouse models of obesity were enriched for 
myofibroblasts and stiffness-promoting ECM components. These differences were related to varied adipose stromal cell (ASC) 
characteristics because ASCs isolated from obese mice contained more myofibro- blasts and deposited denser and stiffer ECMs 
relative to ASCs from lean control mice. Accordingly, decellularized matrices from obese ASCs stimulated mechanosignaling 
and thereby the malignant potential of breast cancer cells. Finally, the clinical relevance and translational potential of our 
findings were supported by analysis of patient speci- mens and the observation that caloric restriction in a mouse model 
reduces myofibroblast content in mammary fat. Collectively, these findings suggest that obesity-induced interstitial 
fibrosis promotes breast tumorigenesis by altering mammary ECM mechanics with important potential implications for 
anticancer therapies. 
 
INTRODUCTION 
Obesity, with increasing worldwide prevalence, is a key risk factor for 
the development and prognosis of breast cancer (1). This correlation 
has been commonly attributed to obesity-mediated differences in adi- 
pose endocrine functions (2). However, given the critical role of contex- 
tual cues in tumorigenesis, obesity-mediated alterations to the local 
microenvironment may also be important. In particular, obesity in- 
duces fibrotic remodeling of adipose tissue (3), and these changes have 
been associated with malignant potential (4). Nevertheless, the exact 
mechanisms through which interstitial fibrosis in obese adipose tissue 
may affect the pathogenesis of breast cancer remain largely elusive. 
Similar to obesity, tumors also feature fibrosis in the surrounding stroma, 
which is commonly referred to as desmoplasia. The concomitant changes in 
extracellular matrix (ECM) density and rigidity not only enable detection by 
mammography and palpation, respectively, but also represent important 
risk factors for tumor development, progression, and response to therapy 
(5, 6). More specifically, enhanced stiffness changes cellular mechano- 
signaling (7), which, in turn, stimulates more aggressive behavior in 
cancer cells through various mechanisms including perturbed epithelial 
morphogenesis (8), growth factor and cytokine signaling (9), and stem 
cell differentiation (10, 11). However, whether obesity-associated fibrot- 
ic remodeling alters local ECM mechanical properties and whether 
these differences activate protumorigenic mechanotransduction remain 
to be elucidated. 
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Myofibroblasts are major cellular regulators of fibrotic and desmo- 
plastic remodeling and, thus, tissue mechanical properties (12). Myofi- 
broblasts are highly contractile and assemble a fibronectin- and collagen 
type I–rich ECM that is characterized by enhanced density, fibrillar 
architecture, cross-linking, and partial unfolding—all parameters causally 
linked to increased ECM stiffness (11–13). Various proinflammatory cyto- 
kines enhanced during obesity [for example, transforming growth factor–b1 
(TGF-b1) (14)] can initiate myofibroblast differentiation in mesenchymal 
cells, including adipose stem cells (ASCs) (11). Nevertheless, the impact of 
obesity on myofibroblast content of mammary adipose tissue remains un- 
certain as most previous studies were performed with subcutaneous and 
visceral fat. Extrapolation of such results to mammary fat should be avoided 
because both global functions (15) and fibrotic remodeling (16) of adipose 
tissue can vary significantly between anatomic depots. 
Here, our goal was to characterize the role of obesity in interstitial 
fibrosis in mammary fat, determine the impact of these variations on 
ECM mechanical properties, and assess whether these changes enhance 
myofibroblast content and the malignant potential of mammary tumor 
cells due to altered mechanotransduction. We have applied a multi- 
disciplinary approach that integrates biological and physical techniques 
to mouse and human samples, ultimately extending our quantitative 
understanding of the functional relationship between obesity-induced 
alterations in ECM mechanics as it pertains to enhanced breast carci- 
nogenesis. Consequently, the risk and prognosis of breast cancer pa- 
tients may be more accurately predicted, and therapeutic interference 
with the suggested relationship may improve patients’ outcomes. 
 
 
RESULTS 
Obesity increases interstitial fibrosis in mouse  mammary fat                                                                                
pads To quantify fibrotic remodeling, we assessed myofibroblast 
content and related ECM changes in mammary adipose tissue harvested 
from two 
 
 
 
established mouse models of obesity. Diet-induced obesity was achieved 
by feeding a high-fat diet to female C57BL/6J mice for 10 weeks start- 
ing at 5 weeks of age (Fig. 1A). Obesity was reflected by increased 
weight of these mice relative to lean control animals fed a low-fat diet 
(29.7 ± 4.2 g versus 21.2 ± 0.6 g; mean ± SD, n = 20 per group). Addi- 
tionally, we used female ob/ob mice, which are morbidly obese com- 
pared to age-matched wild-type mice (54.4 ± 2.9 g versus 19.8 ± 1.5 g; 
mean ± SD, n = 10 per group) (Fig. 1A) owing to a loss-of-function mu- 
tation in the gene encoding the satiety hormone leptin (17). Histological 
evaluation of hematoxylin and eosin (H&E)–stained sections showed 
global differences of obese versus lean breast adipose tissue, including 
larger adipocytes (Fig. 1B). Additionally, immunofluorescence analysis 
suggested that both diet- and genetically induced obesity enhanced levels 
of interstitial a–smooth muscle actin (a-SMA), a myofibroblast marker, 
relative to the respective controls (Fig. 1C). This was further confirmed 
by Western blot analysis of mammary adipose tissue from diet-induced 
mouse models. The levels of fibronectin, an ECM component primarily 
deposited by myofibroblasts (12), were also enhanced in obese animals 
(Fig. 1D). 
High-fat diet increased a-SMA and fibronectin content in the mam- 
mary adipose tissue of both ovary-intact mice and ovariectomized mice 
(fig. S1, A to C). These data suggest that the profibrotic changes after meno- 
pause are relevant to postmenopausal breast cancer, which is where the 
link between obesity and risk of breast cancer is clearest (18). Ovariec- 
tomy did not further stimulate a-SMA in response to high-fat diet rela- 
tive to intact animals (P = 0.97, Student’s t test), although ovariectomy 
with high-fat diet increased mouse weight compared with high-fat diet 
alone [24.4 ± 2.8 g (ovariectomy/low-fat diet); 38.9 ± 2.9 g (ovariectomy/ 
high-fat diet); 29.74 ± 4.15 g (high-fat diet); mean ± SD, n = 20 per group]. 
Although this increase in weight is accompanied by elevated mammary 
gland inflammation (19), our results imply that inflammation may not 
be the sole regulator of obesity-induced fibrosis. 
In addition to fibrosis, tissues were analyzed for the effect of obesity 
on ECM structure. Second harmonic generation (SHG) imaging was 
 
 
Fig. 1.  Obesity increases interstitial fibrosis in mouse mammary fat pads. 
(A) Schematic showing the dietary [high-fat diet (HFD) and low-fat diet (LFD), 
15 weeks] and genetic [ob/ob and wild-type (WT), 11 weeks] mouse models 
of obesity that were used to compare fibrotic remodeling between lean and 
obese mammary fat. (B) H&E-stained sections of mammary fat from lean and 
obese mice. Scale bars, 200 mm. (C and D) Immunofluorescence and Western 
blot analysis of a-SMA (C) and fibronectin (Fn) (D) in mammary fat. Scale 
bars, 200 mm. Western blot quantification is relative to the corresponding 
HSP90 levels. (E) SHG imaging of collagen fiber linearity in mammary fat. 
Box plots show medians with whiskers from minimum to maximum values. 
Scale bars, 100 mm. (C to E) Data are means ± SD (n = 6 to 11 per group). 
*P < 0.05, **P < 0.01, unless otherwise noted, by unpaired Student’s two- 
tailed t tests for two conditions and one-way analysis of variance (ANOVA) 
for multiple comparisons. DAPI, 4′,6-diamidino-2-phenylindole. 
 
 
 
used to quantify ECM structural changes. Interstitial collagen was more 
linearized in mammary adipose tissue of obese animals in both diet- and 
genetically induced obesity models (Fig. 1E). Thus, obesity caused struc- 
tural changes of collagen that have been previously associated with 
ASC-mediated ECM remodeling, enhanced stiffness, and tumor malig- 
nancy in mice and humans (11, 13, 20). In summary, obesity initiates 
fibrotic remodeling of mammary adipose tissue by triggering molecular, 
cellular, and ECM structural changes. 
 
Obesity enhances the profibrotic phenotype of ASCs 
To investigate cellular and molecular differences in obese and lean 
animals, we compared both the myofibroblast content and the ECM 
remodeling capacity of ASCs isolated from adipose tissue (Fig. 2A). 
Only a small quantity of ASCs can be isolated from mammary adipose 
tissue, and differences in mammary fat were comparable to those present 
in inguinal (a mix of subcutaneous and mammary) depots (fig. S2, A to 
C); thus, ASCs were isolated from the stromal vascular fraction of 
inguinal adipose tissue from age-matched wild-type and ob/ob mice 
(20.2 ± 1.4 g versus 56.6 ± 3.3 g; mean ± SD). Indeed, ASCs from obese 
mice were enriched for a-SMA+ myofibroblasts (Fig. 2B). Furthermore, 
these cells also exhibited enhanced proliferative capacity (Fig. 2C) and 
secreted more stromal cell–derived factor 1 (SDF-1) (Fig. 2D)—both 
markers of myofibroblasts or activated fibroblasts (21, 22)—than their 
lean counterparts. Finally, as compared to wild-type ASCs, ob/ob ASCs 
assembled thicker ECMs enriched with collagen and fibronectin (Fig. 2, 
E and F), further confirming the profibrotic phenotype of these cells. 
Next, we verified that the above-described cellular changes were uni- 
versal rather than limited to the genetic makeup of ob/ob ASCs. We 
performed experiments with ASCs isolated from the diet-induced mouse 
model of obesity as well as ob/ob ASCs supplemented with leptin to 
 
 
 
Fig. 2. Obesity enhances the profibrotic phenotype of ASCs. (A) Sche- 
matic showing ASC isolation from inguinal fat of age-matched lean and obese 
mice. (B) Immunofluorescence analysis of a-SMA+ ASCs isolated from ob/ob 
relative to WT fat. Western blot analysis of a-SMA relative to b-actin. (C) Per- 
centage of a-SMA+ and BrdU+ ASCs as analyzed by immunofluorescence. 
(D) SDF-1 secretion of WT and ob/ob ASCs as determined by enzyme- 
linked immunosorbent assay (ELISA) and normalized to DNA content. (E) 
Confocal analysis of collagen type I or fibronectin deposition by WT and 
ob/ob ASCs. (F) Western blot quantification of fibronectin deposition rela- 
tive to b-actin. (G) Comparison of ASCs isolated from low-fat diet– and 
high-fat diet–fed mice for a-SMA levels and BrdU incorporation by immu- 
nofluorescence; SDF-1 secretion by ELISA; and fibronectin matrix deposition 
by confocal microscopy. Scale bars, 200 mm. (B to G) Data are means ± SD 
(n = 3 to 6 per condition). P values by unpaired two-tailed t tests. 
 
 
 
reconstitute the leptin-mediated effects on cellular phenotype that are 
independent from satiety regulation. ASCs isolated from inguinal fat of 
mice fed a high-fat diet had elevated a-SMA levels, proliferative capacity, 
SDF-1 secretion, and matrix deposition, similar to ASCs from ob/ob mice 
(Fig. 2G). Leptin supplementation did not mitigate the increased profibrotic 
potential of ob/ob ASCs because neither a-SMA levels nor fibronectin 
deposition significantly decreased with this treatment (fig. S3, A and B). 
Collectively, these results suggest that obesity promotes ECM remodel-  
ing by increasing the myofibroblast content of the adipose stromal vascular 
fraction in both diet- and genetically induced mouse models of obesity, 
regardless of ovary function. Thus, we performed all following 
experiments with ob/ob ASCs. 
 
Obesity-associated ASCs deposit partially unfolded and stiff ECMs 
Given that myofibroblast-mediated changes of ECM composition and 
structure can increase malignancy by changing microenvironmental 
stiffness, we next tested whether the obesity-mediated effects on ASCs 
translate to altered ECM mechanics. Although increased rigidity of fibrot- 
ic and tumor tissue is typically believed to reflect alterations in collagen 
synthesis and cross-linking (13), variations in the fibronectin matrix 
structure and mechanics may be equally important. In fact, cellular dep- 
osition and remodeling of fibronectin is critical to the formation and 
turnover of collagen I–based ECMs (23), and both fibronectin conforma- 
tional and mechanical changes may play an important role in this process 
(24, 25). Förster resonance energy transfer (FRET) analysis of fibronectin 
conformation indicated that ASCs isolated from obese mice partially un- 
fold fibronectin matrix fibers (Fig. 3, A and B) thereby mimicking fibro- 
nectin changes mediated by tumor-associated ASCs (26). 
Partial fibronectin unfolding may change cellular behavior not only 
by exposing cryptic sites (27) or disrupting strain-sensitive binding sites, 
such as the a5b1 integrin binding site (28), but also by directly elevating 
fibronectin fiber rigidity (26). To confirm that obesity affects the rigidity of 
ASC-deposited ECMs at the cellular/matrix level, we performed quasistatic 
compressive measurements with the surface forces apparatus (SFA) (Fig. 3C) 
(27). Our results verified that obesity elevates matrix rigidity (Fig. 3D), a 
phenomenon associated with malignancy (8). The determined elastic moduli 
were relatively low compared with previously reported tumor stiffness (8), 
given our specific sample preparation technique (measurements of decellu- 
larized, nonfixed ECMs immersed in saline). Nevertheless, they are relevant 
because the stiffness of ECMs deposited by tumor-conditioned ASCs un- 
der the same experimental conditions was ina similar compliant range 
and was increased relative to control ASCs (27). Lastly, analysis of in- 
terstitial mechanics of breast tissue from wild-type and ob/ob mice with 
atomic force microscopy (AFM) nanoindentation further validated that the 
 
 
 
Fig. 3. Obesity-associated ASCs deposit partially unfolded and stiffer 
ECMs. (A) FRET analysis of fibronectin conformation in ECMs deposited by 
WT or ob/ob ASCs. Schematic shows separation of donor (Do) and acceptor 
(Ac) fluorophores due to partial fibronectin unfolding. Pseudocolored im- 
munofluorescence micrographs depict FRET intensities of fibronectin fibers 
in the different ECMs. Scale bars, 50 mm. (B) Representative histogram of 
FRET intensity distribution as analyzed from the fields of view shown in (A). 
Box and whisker plots of FRET intensities as analyzed from six to eight rep- 
resentative fields of view per condition. Data are medians with whiskers 
from minimum to maximum values. (C) SFA indentation analysis of decellu- 
larized ECMs between two silvered mica surfaces mounted on a cantilever 
spring of constant k. F is normal force; R is the radius of curvature of the 
cylindrical discs; D0 and D are the undistorted and force-applied thicknesses 
of the matrix, respectively. (D) Compressive elastic moduli of decellular- 
ized ECMs with corresponding fibronectin immunofluorescence micro- 
graphs. Box plots show medians with whiskers from minimum to maximum 
values from four random fields per condition. Scale bars, 100 mm. (E) AFM 
analysis to assess the elastic moduli of interstitial mammary fat. (Left) 
Picrosirius Red–stained histological cross sections showing representative 
regions of analysis. (Middle) Representative force versus indentation curve. 
(Right) Data are average compressive elastic moduli ± SD, analyzed from 
four samples per condition (20 areas per sample). Scale bars, 100 mm. P values 
in (B), (D), and (E) were determined by unpaired two-tailed t tests. PBS, 
phosphate-buffered saline. 
 
 
 
stiffness of interstitial adipose tissue increases with obesity (Fig. 3E). Con- 
sequently, obesity affects the mechanical properties of the ECM 
deposited by ASCs, which may ultimately lead to interstitial stiffening. 
ASCs isolated from visceral fat of ob/ob mice similarly exhibited 
enhanced profibrotic potential compared with those from the wild-type, 
as detected by elevated a-SMA and fibronectin content and partial un- 
folding of deposited fibronectin matrices (fig. S4, A to C). However, in 
wild-type animals, visceral fat not only contained fewer a-SMA+ASCs 
than inguinal fat (24.8 ± 2.4% versus 39.2 ± 16.2%; mean ± SD, n =3 
per group), but visceral fat–derived wild-type ASCs also deposited less 
ECM compared with wild-type ASCs from inguinal fat (fig. S4D). These 
results suggest that obesity may alter the mechanical properties of adipose 
interstitial tissue at varying anatomical depots, but that the extent of these 
changes may be enhanced at inguinal relative to visceral sites. 
 
ECM deposited by obesity-associated ASCs promote 
myofibroblast differentiation via altered  mechanosignaling 
We next tested whether the changes in ECM physicochemical properties 
directly contribute to the increased levels of myofibroblasts in obese adipose 
tissue (fig. S5A) because it has been shown that elevated ECM stiffness can 
promote myofibroblast differentiation (29). Wild-type ASCs exhibited 
enhanced a-SMA levels when cultured on decellularized matrices depo- 
sited by ob/ob ASCs versus wild-type ASCs, whereas the wild-type ECMs 
did not affect a-SMA protein expression in ob/ob ASCs (fig. S5B). The 
presence of the Rho-associated protein kinase (ROCK) inhibitor Y27632 
did not elevate a-SMA in wild-type ASCs cultured in ob/ob ECM, indi- 
cating that ECM-induced differences were related to varied cell contrac- 
tility and, thus, mechanotransduction. Inhibition of cell contractility with 
Y27632 reduced a-SMA in ob/ob ASCs on both types of decellularized 
ECM (fig. S5B), consistent with previous findings that contractility is 
mandatory for maintenance of the myofibroblast phenotype (30). 
The amount of endogenously sequestered TGF-b was similar in both 
types of decellularized ECM (fig. S5C), and saturating TGF-b–binding 
sites in the different ECMs (by incubation with exogenous TGF-b be- 
fore cell seeding) had no significant effect on a-SMA protein expression 
(fig. S5D). Differential mechanical activation of latent, ECM-sequestered 
TGF-b (31) was not responsible for the myofibroblastic cell popula- 
tion because we observed no marked difference in a-SMA levels when 
latency-associated peptide (LAP), a cellu- 
lar force transmission molecule, was func- 
tionally inhibited (fig. S5D). Collectively, 
these findings suggest that the varied ECM 
physicochemical properties of obese inter- 
stitial adipose tissue provide a direct, TGF- 
b–independent positive feedback mechanism 
that elevates myofibroblast content in obese 
adipose tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. ECMs deposited by obesity-associated ASCs stimulate MDA-MB231 mechanosensitive 
growth. (A) Experimental setup to analyze human breast cancer cell line MDA-MB231 behavior in response 
to decellularized WT and ob/ob ECMs. (B) Number of MDA-MB231 cells after culture on decellularized ob/ob 
or WT ECMs as determined by image analysis. Scale bar, 100 mm. (C) Immunofluorescence analysis of pFAK[397]+ 
MDA-MB231 (red arrows) after culture on the different ECMs and corresponding Western blot analysis of 
pFAK[397] relative b-actin. Scale bars, 50 mm. (D) Immunofluorescence analysis of the nuclear/cytoplasmic 
YAP/TAZ ratio of MDA-MB231 after culture on ob/ob or WT ECMs. Scale bars, 50 mm (top); 20 mm (bottom). 
P values in (B) to (D) determined by unpaired two-tailed t tests. (E) Effect of Y27632 on MDA-MB231 growth 
on ob/ob or WT ECMs as assessed by image analysis of cell number. *P < 0.05 versus all other groups, 
determined by two-way ANOVA. (B to E) Data are means ± SD (n = 3 per condition). 
Obesity-associated ASCs 
stimulate breast cancer 
mechanosensitive growth 
Next, we examined the impact of obesity- 
associated ECM remodeling on mammary 
tumor cells by seeding MDA-MB231 hu- 
man breast cancer cells onto decellularized 
matrices assembled by age-matched wild- 
type and ob/ob ASCs (Fig. 4A). In line with 
the observation that ASC-derived myofi- 
broblasts deposit ECMs that promote breast 
cancer cell proliferation (11), MDA-MB231 
growth was significantly enhanced on ob/ob 
ECMs (Fig. 4B). Given that ob/ob ASCs can 
unfold fibronectin, which in turn can alter 
cell behavior by modulating binding speci- 
ficity of synergy-dependent (for example, 
a5b1) and non–synergy-dependent (for 
example, avb3) integrins (28, 32), we first 
tested whether the detected differences in 
tumor cell growth were due to fibronectin 
conformation–dependent variations in a5b1 
and avb3 engagement. Supplementation of 
neither a5b1 nor avb3 function–blocking 
antibodies significantly affected MDA-MB231 
growth on wild-type or ob/ob matrices (fig. 
S6A). These data indicate that fibronectin 
conformational changes are not primarily 
responsible for the differential tumor cell 
 
 
 
response, leading us to investigate ECM-induced differences in tumor 
cell mechanosignaling. 
Increased stiffness stimulates tumor cell growth by altering mechano- 
transduction in a sequence of events, including enhanced RhoA/ROCK- 
mediated cell contractility, phosphorylation of focal adhesion kinase 
(pFAK), and ultimately YAP/TAZ transcription factor activity (33, 34). 
We found that MDA-MB231 cells contained not only more pFAK 
(Fig. 4C) but also more nuclear YAP/TAZ (Fig. 4D) when seeded onto 
ECMs deposited by ob/ob compared with wild-type ASCs. Moreover, 
inhibition of cell contractility with the ROCK inhibitor Y27632 blocked 
the growth-promoting effect of ECMs deposited by ob/ob ASCs (Fig. 4E), 
which was paralleled by a reduction in pFAK (fig. S6B). These data 
imply that obesity-induced interstitial ECM stiffness promotes tumor 
cell growth by altering cell contractility–dependent signal transduction. 
Obesity-associated differences in local interstitial stiffness are rele- 
vant even to tumor cells not directly in contact with these sites, as the 
increased levels of SDF-1 secreted by obese ASCs (Fig. 2D) stimulated 
MDA-MB231 migration via the SDF-1/CXCR4 signaling axis as com- 
pared to a similar number of lean ASCs (fig. S6C). 
 
Obesity-associated ECMs promote the tumorigenic potential 
of premalignant human breast epithelial cells 
To assess whether the detected differences in obesity-associated ECM 
remodeling also drive the transformation of premalignant cells, we 
performed experiments with premalignant MCF10AT human breast 
epithelial cells (35). Indeed, ob/ob ASC–derived decellularized ECMs 
promoted the growth of MCF10AT cells because of matrix-induced 
changes in cell contractility as confirmed by blockade of Rho/ROCK 
signaling with Y27632 (Fig. 5A). 
Additionally, we tested the effect of the different matrices on the 
disorganization of three-dimensional (3D) MCF10AT acini, a hallmark 
of malignant transformation (8, 36). Structurally intact MCF10AT 
mammary acini were seeded onto either wild-type or ob/ob ECMs 
(Fig. 5B). Acini cultured on ob/ob matrices were significantly more dis- 
organized relative to acini cultured on the corresponding wild-type 
matrices (Fig. 5C). To confirm that these differences were not solely 
due to changes of cell proliferation, we analyzed MCF10AT cell migra- 
tion on the different ECMs. The ob/ob ECMs promoted the migration 
of premalignant MCF10AT cells along ECM fibers (Fig. 5D, i) and away 
from their original position (Fig. 5D, ii) more so than did wild-type 
ECMs. Additionally, quantification of motility over the course of 5 hours 
confirmed the increased migration speed of MCF10AT cells on ob/ob 
ECMs (Fig. 5D, iii). 
 
Obesity-associated ECM remodeling also occurs in human 
breast tissues 
To determine the clinical relevance of our findings in mice and in vitro 
with human cell lines, we analyzed tumor-free breast tissue from nor- 
mal, overweight, and obese patients. Spe- 
cimens were derived from a previously 
published cohort of patients undergoing 
mastectomy (37) and were collected from 
either the contralateral breast or from parts 
not involved by the tumor to ensure that 
only noncancerous breast tissue was ana- 
lyzed. a-SMA levels were increased in obese 
humanbreast tissue (Fig. 6A), and SHG im- 
aging indicated a corresponding increase in 
collagen fiber aligned length (Fig. 6B). 
Consistent with in vitro results (fig. S5), 
a-SMA levels in these tissues did not cor- 
relate with TGF-b expression, but did with 
obesity-associated ECM remodeling such 
as the amount of deposited fibronectin and 
collagen fiber thickness; a trend, but no sta- 
tistical significance was noted for collagen 
fiber aligned length. In addition, a-SMA 
levels positively correlated with inflamma- 
tion [indicated by crown-like structure of 
the breast (CLS-B) index] (Fig. 6C), confirm- 
ing results from others that macrophage- 
derived factors may in part contribute to 
Fig. 5. Obesity-associated ECMs promote the tumorigenic potential of premalignant human breast 
epithelial cells. (A) Number of MCF10AT cells after culture on WT or ob/ob ECMs in the presence and ab- 
sence of Y27632. Data are means ± SD (n = 3). *P < 0.05 versus all other groups, determined by two-way 
ANOVA. Scale bars, 50 mm. (B) Methodology used to assess the effect of WT and ob/ob ECMs on the disor- 
ganization of MCF10AT acini. Spreading was analyzed by measuring acini surface area and height. (C) Con- 
focal image analysis of surface area and height of acini and representative confocal micrographs of intact 
versus spread MCF10A acini (n = 100 acini per condition). Horizontal lines indicate means. Scale bar, 50 mm. 
(D) Time-lapse imaging of MCF10AT migration on ob/ob relative to WT ECMs. (i) Representative image sequence 
visualizing MCF10AT migration along fibronectin fibers. Scale bar, 20 mm. (ii) x-y coordinate maps tracking in- 
dividual cells over 300 min. (iii) Computed MCF10AT motility from (ii) (n = 41 cells per condition). Horizontal lines 
indicate means. P values in (C) and (D) determined by unpaired two-tailed t tests. FOV, field of view. 
the increased levels of ECM remodeling 
in obese mice (38). The integrated effects 
of several obesity-associated parameters 
may therefore be necessary to accurately 
predict the risk of obesity-associated pro- 
tumorigenic matrix remodeling. 
Additionally, we analyzed desmoplas- 
tic remodeling in breast cancer specimens 
collected from lean and obese women. 
Pathological scoring of H&E-stained 
 
 
 
cross sections of varied subtypes (table S1) revealed that tumors from 
obese patients exhibited more severe desmoplasia relative to tumors 
from lean patients (Fig. 7A, fig. S7, and table S1). Immunofluorescence 
analysis confirmed increased levels of a-SMA+ cells and fibronectin in 
samples from obese patients compared with lean ones (Fig. 7, B and C). 
Moreover, obesity induces collagen-dependent structural changes that 
likely contribute to enhanced mechanical rigidity because samples from 
obese patients exhibited an increase not only in collagen fiber thickness 
but also in fiber aligned length (Fig. 7D). 
Lastly, we confirmed that the differential ECM properties of 
obese human tumors correlated with enhanced mechanotransduction. 
In agreement with our in vitro results (Fig. 4D), the epithelial compart- 
ment of tumors from obese patients not only exhibited elevated overall 
levels of YAP/TAZ but also greater nuclear accumulation relative to 
tumors from lean patients (Fig. 7E). The detected changes in obesity- 
associated ECM remodeling may thus correspond to elevated mechano- 
signaling in obese tumors and play a key role in the worse clinical 
prognosis of obese cancer patients (18). 
In a larger cohort, we performed bioinformatic analysis of genes dif- 
ferentially expressed in estrogen receptor–positive (ER+) breast cancer 
in obese and nonobese patients (39). Consistent with our findings that 
obesity promotes ECM-dependent mechanotransduction, which corre- 
lates with inflammation, we found that obesity leads to enrichment of 
functional pathways associated with ECM-, adhesion-, and inflammation- 
related gene signatures in breast cancer patients (table S2). Further analysis 
of these obesity-associated, ECM-related (n = 49), and inflammation- 
related (n = 13) genes revealed a subset of eight genes common to both 
pathways (Fig. 7F). These eight genes were checked for coexpression 
with the other ECM-specific genes that were not common to the 
ECM- and inflammation-related subset, to understand their interaction 
with the other genes in the ECM pathway. This analysis indicates a 
strong correlation between ECM- and inflammation-related genes in 
obese ER+ breast cancer patients showing that the eight genes were sig- 
nificantly coexpressed with other ECM-related genes [false discovery 
rate (FDR) < 0.2]. Moreover, expression of two YAP/TAZ-regulated 
genes (CTGF and ANKRD) (34), identified from a previously de- 
scribed ECM density–based gene signature (7), were correlated signif- 
icantly (FDR < 0.2) with a subset of these eight genes, suggesting a 
possible co-regulation between obesity, mechanotransduction, ECM, 
and inflammation in ER+ breast cancer patients (tables S2 and S3). 
 
 
 
Fig. 6. Obesity-associated, tumor-free human breast tissue displays profibrotic features. (A and B) 
Immunofluorescence analysis of a-SMA levels (A) and SHG image analysis of collagen fibers (B) in tumor- 
free breast tissue from normal, overweight, and obese women. Scale bar, 100 mm (A); 50 mm (B). Data are medians 
with minimum and maximum values from 9 to 11 samples per group. P values by one-way ANOVA. (C) Corre- 
lation of a-SMA levels with fibronectin levels (determined by immunofluorescence), collagen fiber thickness and 
length (analyzed by SHG), TGF-b expression (measured by quantitative reverse transcriptase polymerase 
chain reaction), and obesity-associated chronic inflammation (as defined by CLS-B index). Spearman’s rank 
correlation was used to determine P values, and its coefficient was denoted as rho (r). Data points represent 
individual samples (n = 28). 
Caloric restriction decreases 
fibrotic features in mammary 
fat of obese mice 
The therapeutic value of elective weight 
loss is unresolved at both the clinical and 
physiological levels, including the rever- 
sal of adipose tissue interstitial fibrosis 
(16, 40). Therefore, we tested whether 
caloric restriction could reduce intersti- 
tial fibrosis in mammary fat. Ovariecto- 
mized mice were subjected to 10 weeks 
of high-fat diet to mimic postmenopausal 
obesity, followed by 7 weeks of caloric re- 
striction to suppress further weight gain, 
according to our previous reports [22.1 ± 
0.6 g (low-fat diet); 38.9 ± 2.2 g (high-fat 
diet); 30.1 ± 0.8 g (high-fat diet/caloric 
restriction)] (fig. S8A) (41). Caloric restric- 
tion reduced the content of myofibro- 
blasts in mammary fat interstitial tissue; 
a similar, albeit not significant, trend was 
noted for fibronectin (fig. S8, B and C). 
These data suggest that caloric restriction 
can reverse features of fibrotic remodel- 
ing in mammary adipose tissue. Howev- 
er, longer-term follow-up will be required 
to determine whether these cellular changes 
translate to differences in ECM physico- 
chemical properties and to extend this to 
clinical specimens. 
 
 
DISCUSSION 
Our results demonstrate that obesity leads 
to the formation of mechanical niches in 
adipose tissue that mimic characteristics of 
 
 
 
tumor-associated stroma and promote carcinogenesis by altering 
mechanotransduction. More specifically, obesity increases the number 
of myofibroblasts in mammary adipose tissue, which, in turn, deposit 
a more fibrillar, partially unfolded, and stiffer ECM. This altered ECM 
not only provides a positive feedback mechanism for further myofi- 
broblast differentiation but can also increase the malignant behavior 
of mammary epithelial cells. Collectively, our results suggest that altered 
ECM physicochemical properties not only are a hallmark of already 
established tumors but may also be responsible for the increased risk 
and worse clinical prognosis of obese breast cancer patients. The de- 
tected changes in obesity-associated ECM remodeling correlated with 
inflammation, a known hallmark of both tumorigenesis and obesity  
(3, 42). Hence, our findings provide a new perspective on the tumor- 
promoting capability of inflammation (2). 
Although obesity induces fibrosis in subcutaneous and visceral adi- 
pose tissue (16), our results show that similar changes also occur in mam- 
mary adipose tissue. This observation is important given that (i) the global 
functions and fibrotic remodeling of adipose tissue vary between ana- 
tomic depots (4, 16) and (ii) the local mi- 
croenvironment of the breast is indisputably 
relevant to mammary tumorigenesis (43). 
Obesity also caused fibrotic remodeling 
in mammary fat from ovariectomized 
mice, further suggesting that obesity- 
associated stiffening of the ECM occurs 
independently of hormone status and is 
therefore pertinent to both pre- and post- 
menopausal breast cancers. The levels 
of obesity-associated fibrotic remodeling 
were the same in control and ovariecto- 
mized mice, although the latter featured 
increased body weight and inflammation 
(19). Hence, it is possible that a threshold 
for inflammation-mediated fibrotic changes 
exists. Nevertheless, it is also conceivable 
that ovariectomy counterbalances some 
of the profibrotic effects mediated by 
obesity/inflammation because reduced 
estrogen levels can diminish fibrosis (44). 
The described obesity-associated changes 
in ECM physicochemical characteristics 
were related to an increase of myofibro- 
blasts (11), which elevated matrix stiff- 
ness consistent with previous reports, for 
instance, by increasing ECM quantity (8), 
collagen alignment (45), and fibronectin 
unfolding (27). Obesity-associated ECMs 
elevated ASC contractility and thus myo- 
fibroblast differentiation, a mechanism 
also reported for cancer-associated fibro- 
blasts (30). Nevertheless, increased myo- 
fibroblast content in obese breast tissue 
may also arise from alternative mecha- 
nisms including increased recruitment of 
bone marrow mesenchymal cells (46) or 
altered adipocyte-macrophage crosstalk 
(38). In addition to changing ASC behav- 
ior, obesity-associated ECMs increased 
Fig. 7. Obesity-associated ECM remodeling in patient samples. (A) Histopathological scoring of 
clinical tumor specimens for degree (1 to 3) of desmoplasia (n = 17 to 18 patients per group). Scale 
bars, 200 mm. Statistical significance was assessed by Fisher’s exact test. (B and C) Immunofluorescence 
analysis of a-SMA (B) and fibronectin (C) content in breast tumor specimens from obese and lean pa- 
tients (n = 10 patients per group). (D) SHG image analysis of collagen fiber thickness and length. Data are 
medians with minimum and maximum values (n = 10 patients per group). P values in (B to D) were 
determined by Mann-Whitney U tests. (E) Immunofluorescence image analysis of epithelial total and nuclear 
YAP/TAZ in tumors. Data points are individual images (n =10 images per patient, 10 patients per group). 
P values by mixed-model design ANOVA. Scale bars, 100 mm. (F) Bioinformatics analysis of published data (39) 
to correlate obesity-induced transcriptomic changes with ECM- and inflammation-related gene signatures. 
the malignant behavior of MDA-MB231 
and premalignant MCF10AT human breast 
cancer cells. Hence, obesity-associated 
changes in breast adipose tissue intersti- 
tial stiffness not only promote aggres- 
sion of already existing tumors but 
may also contribute to the transforma- 
tion of early-stage breast cancer. This 
is particularly relevant because obese 
 
 
 
ASCs secrete enhanced levels of SDF-1–stimulating cellular recruitment 
to sites of protumorigenic ECM remodeling. However, whether dif- 
ferent tumor subtypes may vary in their responsiveness to obesity- 
associated ECM changes should be confirmed with primary cells and 
patient samples stratified by tumor subtype. 
Using specimens from lean and obese patients as well as testing the 
effect of caloric restriction on fibrotic remodeling of mammary fat, we 
provide experimental evidence supporting the clinical relevance of our 
results. We demonstrated not only that obesity promotes features of fi- 
brotic remodeling in cancer-free breast tissue but also that obesity 
worsens desmoplasia and the related ECM changes in mammary tumors. 
Weight loss and exercise are routinely recommended for obese cancer 
patients because this regime may improve the clinical outcome of 
cancer patients (47). A number of possibilities including altered me- 
tabolism (48) and reduction of local inflammation may contribute to 
this end (41). Additionally, our data in obese, ovariectomized mice 
suggest that caloric restriction can reverse fibrotic remodeling; a simi- 
lar trend was noted for ECM remodeling, although the effect may be 
delayed relative to cellular changes (49). Furthermore, the length of 
exposure to altered ECM physicochemical properties may influence 
the capability of ASC-derived myofibroblasts to lose their contractile 
phenotype in response to dietary intervention (29). 
On the basis of our reported results, a number of questions arise. The 
initial obesity-associated mechanisms elevating ECM mechanics are yet 
unknown. Obesity-associated hypoxia may be responsible, given its 
ability to up-regulate collagen cross-linking and, thus, ECM stiffness 
(13, 50). Alternatively, obesity-associated chronic inflammation may 
play a role. However, whether inflammation is the driver or rather a 
consequence of ECM remodeling remains to be confirmed. Our patient 
genetic data suggest a connection between obesity, ECM remodeling, 
inflammation, and mechanotransduction, but more patients will be 
necessary to discern the strength of this connection and whether in- 
flammation contributes to increased stiffness of obese mammary fat 
and tumors. Moreover, obesity-associated fibrosis has been corre- 
lated with elevated levels of collagen type VI and its cleavage product, 
endotrophin (4). Whether the tumor-promoting effects of these 
factors may in part be related to altered ECM mechanics is unclear. 
Although we evaluated the direct effect of obesity-mediated ECM 
differences on ASCs and tumor cells, altered ECM mechanics can 
indirectly promote tumorigenesis, for instance, by influencing solu- 
ble factor (for example, adipokines) signaling and other stromal cell 
responses (2, 27, 33). 
Other than caloric restriction, there are several clinically relevant as- 
pects to our study. Mammography is commonly used for early detection 
of breast cancer and overall risk assessment because women with mam- 
mographically dense breasts have a higher probability of developing 
breast cancer. However, because fat is radiolucent, obese women appear 
to have nondense breast tissue (51), although our data suggest that local, 
microscale density changes still occur. Therefore, alternative high- 
resolution imaging will be necessary to better localize and monitor 
regions that may stimulate tumorigenesis in obese patients. Further- 
more, adipose tissue or ASCs are increasingly being considered for re- 
generative approaches to mastectomy. Thus far, little attention has 
been given to the body habitus of the patient from whom the ASCs 
are isolated, yet our data imply that ASCs from obese individuals 
might promote recurrence of breast cancer relative to ASCs from lean 
patients. Stratification of patients on the basis of obesity-associated 
features may help to better assess the potential risk, if any, associated 
with adipose tissue–based reconstructive approaches (52). Together, 
our results are of broad relevance to the field of obesity-induced 
cancer and inform a multitude of future opportunities in the arena 
of physical sciences in oncology. 
 
 
MATERIALS  AND METHODS 
 
Study design 
This study was designed to investigate the hypothesis that obesity- 
associated fibrosis promotes breast cancer malignancy by altering 
mechanotransduction. In vitro and in vivo experiments were performed 
to analyze obesity-associated ECM physicochemical properties. Tumor 
cell responses to lean and obese ECMs were tested in vitro and con- 
firmed with patient samples. All clinical samples were obtained from 
patients with varying demographic background and were stratified on 
the basis of body mass index. Sample sizes for analysis of mouse and 
cancer-free human samples were based on our previous studies (37). 
Sample sizes for analysis of clinical tumor samples were chosen to detect 
a statistical significance of P < 0.05. For all in vitro studies, three 
independent experiments with at least three samples per condition were 
performed. Outliers were not excluded, but data from human breast tu- 
mors were transformed by either log or square root before statistical 
analysis. Histomorphometric analysis of mouse and patient samples 
was blinded; in vitro experiments were not blinded. 
 
Cell                 isolation                 and                  culture 
ASCs were isolated from the stromal vascular fraction of either inguinal 
(a mix of subcutaneous and mammary) or visceral white fat of both ge- 
netic (11-week-old) and dietary (15-week-old) mouse models via colla- 
genase digestion and density centrifugation (Fig. 2A) (53), as described 
further in the Supplementary Methods. 
 
Analysis of mammary tissue  and  cellular  behavior 
Differences in obesity-associated breast tissue remodeling and corresponding 
changes in cellular behavior were assessed with cultured cells and ex vivo 
mammary tissue by immunostaining, FRET and SHG image analysis, 
Western blot, and SFA and AFM measurements as described in the 
Supplementary Methods. Ex vivo mammary tissues (murine mammary 
fat pads, tumor-free human breast tissue, and human breast tumor spec- 
imens) were isolated as described in the Supplementary Methods. 
 
Statistical analysis 
Microsoft Excel, GraphPad Prism 5, and JMP 11 were used for statis- 
tical analysis. Unless otherwise noted, unpaired Student’s t tests and 
ANOVA with post hoc Tukey’s test were used to compare parametric 
data between two conditions and among multiple conditions, respec- 
tively. Results were also confirmed with the Mann-Whitney U test and 
the Wilcoxon signed-rank test, respectively. Statistical correlation be- 
tween the nonparametric variables of human breast tissue was assessed 
by Spearman’s rank correlation, and its coefficient was denoted as 
rho (r). The effect of obesity on human tumor samples (table S1) was 
tested by Fisher’s exact test. Two-sided testing with normal-based 95% 
confidence interval was performed for each analysis, and P < 0.05 was 
considered statistically significant. In vitro results are shown for one 
representative study after similar results were replicated in three 
separate experiments. An independent statistician was consulted for 
all statistical analyses. 
 
 
 
SUPPLEMENTARY MATERIALS 
Materials and Methods 
Fig. S1. Obesity promotes interstitial fibrosis in breast adipose tissue after menopause. 
Fig. S2. Inguinal depots of adipose tissue feature markers of interstitial fibrosis. 
Fig. S3. The profibrotic potential of ob/ob ASCs is not due to leptin deficiency. 
Fig. S4. Obesity-associated ASCs promote fibrotic ECM remodeling in visceral fat. 
Fig. S5. ECMs deposited by obesity-associated ASCs promote myofibroblast differentiation. 
Fig. S6. Physicochemical cues of ob/ob ECMs modulate MDA-MB231 behavior. 
Fig. S7. H&E images of breast tumors with different subtypes. 
Fig. S8. Caloric restriction decreases fibrosis in mammary fat of obese mice. 
Fig. S9. Decellularized ECMs do not contain cellular residuals. 
Table S1. Subtypes, demographics, and desmoplastic grade of lean and obese breast cancer 
samples. 
Table S2. Gene ontology data analysis. 
Table S3. Correlation of YAP/TAZ-regulated genes with obesity-dependent ECM remodeling/ 
inflammation. 
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Materials and Methods 
 
Animal models and tissue isolation 
 
To characterize obesity-associated interstitial fibrosis mammary, inguinal, or visceral fat 
was isolated from both dietary and genetic mouse models of obesity (n = 10/group). For 
the dietary model, female 5 week-old C57BL/6J mice (Jackson Laboratories) were 
randomized and fed low fat diet (LFD) or high fat diet (HFD) (Research Diets: D12492i, 
10 kcal% fat and 12450Bi, 60 kcal% fat, respectively) ad libitum for 10 weeks as 
previously described (Fig. 1A) (19). For the genetic model, 8 week-old B6.Cg-Lepob/J 
(ob/ob) and their age-matched C57BL/6J wild-type controls (Jackson Laboratories) were 
fed PicoLab Rodent Diet 20, #5053 (W.F. Fisher & Son) ad libitum until sacrifice at 11 
weeks of age (Fig. 1A). In the dietary model, to mimic menopause, either ovariectomy 
(OVX) or sham surgery was performed on C57BL/6J mice at 4 weeks of age. One week 
post-surgery, ovariectomized (OVX) and ovary intact mice were randomized for dietary 
intervention (LFD or HFD) (fig. S1A). To study the effect of caloric restriction, OVX mice 
received 10 weeks of HFD feeding and were subsequently subjected to 30% caloric 
restriction (CR) for 7 weeks using previously established protocols (fig. S8A) (41). Age- 
matched control mice were fed LFD or HFD for a total of 17 weeks (n = 6/group). Isolated 
tissues were formalin fixed for immunohistochemical evaluation, or frozen and stored at -
80°C for subsequent biochemical analysis. Animal protocols were approved by the 
Institutional Animal Care and Use Committees at Weill Cornell Medical College and 
Cornell University. 
Cell isolation and culture 
 
ASCs were isolated from the stromal vascular fraction of either inguinal (a mix of s.c. and 
mammary) or visceral white fat of both genetic (11 week-old) and dietary (15 week- old) 
mouse models via collagenase digestion and density centrifugation (Fig. 2A) (53). Briefly, 
isolated tissue was minced in Krebs-Ringer-HEPES (KRBH) buffer prepared as described 
previously and digested with 1.5 mg/ml collagenase type 1 buffer (Worthington 
Biochemical Corp.). Digested tissue was filtered through a 250-µm cell strainer (Pierce) 
and centrifuged in Histopaque-1077 solution (Sigma) to separate ASCs from adipocytes. 
Isolated ASCs were cultured in media containing 1:1 Dulbecco's Modified Eagle Medium 
(DMEM)/F12 (Gibco) supplemented with 10% FBS (Tissue Culture Biologicals), 1% 
antibiotic (penicillin/streptomycin) (Gibco), up to passage 4. Human MDA-MB231  breast 
cancer cells (ATCC) were cultured in αMEM (Sigma) containing 10% FBS and 1% 
antibiotic. MCF10AT (Barbara Ann Karmanos Cancer Institute) were cultured in 
DMEM/F12 (Gibco) supplemented with EGF (20 ng/ml) (Millipore), hydrocortisone (500 
μg/ml) (Sigma-Aldrich), cholera toxin (100 ng/ml) (Sigma-Aldrich), insulin (10 μg/ml) 
(Sigma-Aldrich), 5% horse serum (Gibco), and 1% antibiotic. 
 
 
Mammary tissue immunostaining and image analysis 
 
Cross-sections were prepared from paraffin-embedded mammary fat and subjected to H&E 
staining and IF (for fibronectin [Fn] and α-SMA). Antigen retrieval was performed with 
0.1-M citrate buffer, pH 6.0 (for α-SMA IF), and additional proteinase K treatment (for Fn 
IF) (Dako). Subsequently, tissue sections were permeabilized and blocked with 
SuperBlock (Thermo Fisher) in 0.05% Tween-20 PBS (PBST). For α-SMA staining, 
M.O.M kit blocking reagent (Vector Laboratories) was used. After overnight incubation 
(4°C) with primary antibodies against Fn (Sigma-Aldrich) or α-SMA (Invitrogen), sections 
were incubated with AlexaFluor 488-conjugated secondary antibody, counterstained with 
4',6-diamidino-2-phenylindole (DAPI), and then mounted with Prolong Gold reagent (all 
from Invitrogen). For each sample, 10 to 20 randomly selected areas (excluding mammary 
epithelial structures) were imaged with a Zeiss Observer Z.1 microscope and an AxioCam 
MRm camera, and average fluorescence intensity was calculated. For α-SMA analysis, α-
SMA associated with glands and vasculature structures was excluded. To correct for 
background, all images were thresholded by subtracting fluorescence intensity of negative 
controls using Adobe Photoshop (n = 10 samples/group). The isolated positive pixels of 
each image were quantified in ImageJ (NIH) and then normalized to the number of 
adipocytes. 
 
 
Characterization of collagen fibers by SHG imaging analysis 
 
Multiphoton SHG imaging was used to characterize collagen structure in fresh mammary 
tissue (genetic mouse model) and rehydrated cross-sections of paraffin-embedded 
mammary tissue (dietary mouse model, human tumor-free breast tissue, human breast 
tumors). Imaging was performed with a custom-built multiphoton microscope using 780- 
nm illumination and an Olympus 20x/0.95W XLUMPlanFl objective (54). Emissions were 
separated into SHG (360-405 nm, pseudocolored purple) and autofluorescence (420-550 
nm, pseudocolored green) channels. For murine samples, mammary tissue from 11 week-
old ob/ob and lean mice (n = 3 samples/condition) was isolated and immersed in PBS. Z-
stacks (50-120 µm in depth) of areas adjacent to the mammary epithelium, as 
identified in transmitted light mode, were acquired at 2-µm intervals; 5 to 6 locations per 
tissue were imaged. For mammary tissue from the dietary mouse model of obesity and 
human specimens, 4-µm cross-sections were deparaffinized, rehydrated, and immersed in 
PBS. Micrographs of 10 regions per sample were collected and a total of 10 specimens per 
condition were analyzed. SHG channel images were extracted and analyzed through a 
custom-built autocorrelation analysis algorithm as previously described (54). To analyze 
collagen structure, a 2D spatial autocorrelation was computed from the SHG channel 
image. An autocorrelation ellipse was generated by fitting to 1/e of the maximum value of 
each image autocorrelation; the mean radius of the ellipse (in pixels) indicates the length 
scale of the collagen framework. The minimum and maximum radius of the ellipse were 
obtained and presented as the correlation thickness and correlation length of the fibers, 
respectively. The correlation thickness and length suggest the thickness and aligned length 
of collagen fibers, respectively. The linearity was determined by calculating the ratio of 
maximum to minimum radius of the ellipse, and this indicates the linearity of collagen 
fibers. 
 
 
Characterization of isolated ASCs 
 
Isolated ASCs were plated on glass coverslips, cultured for 3 to 5 days, fixed with 4% 
paraformaldehyde (PFA), and then immunofluorescently analyzed for α-SMA, 
proliferative capacity, and ECM deposition. To determine proliferation, ASCs were 
incubated with 10 µM bromodeoxyuridine (BrdU) (Sigma-Aldrich) for 20 hours. After 
fixation, cells were pretreated with ice-cold 1-N HCl, 37oC 2-N HCl, and 0.1-M borate 
buffer; incubated with biotinylated mouse anti-BrdU (Invitrogen); and, finally, 
fluorescently labeled with streptavidin-conjugated AlexaFluor 555. For IF of α-SMA, Fn, 
and collagen, fixed cells were permeabilized with 0.05% Triton X-100 (VWR) in PBS 
(PBS-X), blocked in 1% BSA (Fischer Scientific) in PBS, and then incubated with primary 
antibodies directed against α-SMA (Abcam), Fn, and collagen (Millipore) overnight at 4°C. 
Subsequently, samples were labeled with species-specific AlexaFluor 488-conjugated 
secondary antibodies. The percentage of BrdU-positive cells was determined by manually 
counting five representative images for each  sample for a total of three samples. Matrix 
thickness was determined by confocal analysis of Z-stack images (1-µm interval) captured 
with a Zeiss 710 confocal microscope. Differences in ASC secretion of SDF-1 were 
evaluated via SDF-1 ELISA duo set (R&D) following 24 hours of incubation in serum-
starved media and normalized to DNA content as measured from cell lysates by 
QuantiFluor dsDNA System (Promega) (n = 3/group). To assess the role of leptin 
deficiency in enhancing the profibrotic potential of ob/ob ASCs, cells were supplemented 
with 10 ng/ml leptin (R&D) for 5 days prior to analysis. 
 
 
Western blot analysis 
 
Tissue and cell lysates were prepared in RIPA buffer containing protease and phosphatase 
inhibitor cocktail (all from Thermo Scientific) as well as 1mM phenylmethylsulfonyl 
fluoride (Calbiochem). Protein concentrations were measured using a BCA kit (Thermo 
Scientific) and equal amounts of protein samples were loaded on gels (Bio-Rad), separated 
by reducing SDS-PAGE, and transferred to PVDF membranes (Bio-Rad). After blocking 
with 5% milk powder, membranes were incubated overnight (4°C) with primary antibodies 
raised against α-SMA, Fn, fibroblast activation 
protein (FAP) (Millipore) and pFAK [397] (Invitrogen), as well as the house keeping 
proteins HSP90 (Santa Cruz), b-actin (Millipore), and GAPDH (Ambion). Following 
incubation with species-specific HRP-conjugated secondary antibodies (Novus Bio) 
chemiluminescence detection was performed using an ECL kit (Thermo Scientific). 
Densitometric analysis was performed with Image Lab (Biorad), Image J and Adobe 
Photoshop CS4. 
 
 
Analysis of Fn conformation via FRET 
 
Differences in Fn conformation were determined as described previously (26, 55). Briefly, 
2x104 ASCs from ob/ob and wild-type mice were seeded in Lab-Tek chamber slides 
(Thermo Scientific) pre-coated with 30 µg/ml unlabeled Fn (Invitrogen) in PBS (n 
= 3 samples/condition). Subsequently, human plasma Fn (only 8% FRET-labeled Fn with 
an excess of 92% unlabeled-Fn to prevent intermolecular energy transfer between adjacent 
proteins in fibers) was added to yield a final Fn concentration of 50 µg/ml necessary for 
FRET analysis. Twenty-four hours post-incubation, cells were fixed with 4% PFA, washed 
with PBS and then imaged using a Zeiss 710 confocal microscope with a 40x water 
immersion objective under conditions that prevented photobleaching. Z-stack images (1-
µm interval) were captured at 6-8 randomly chosen areas following excitation with a 10% 
laser intensity through the 488 nm channel, and then the signals from both the donor (514-
526 nm) and acceptor (566-578 nm) channels were collected. Image processing of the 
acceptor and donor images was performed as described previously (55). Briefly, MATLAB 
(MathWorks, Inc.) was used to compute the FRET intensity (ratio of acceptor and donor 
channels) of images, to calculate the mean and standard deviation of 
the FRET intensities, and to compile FRET intensity data for histogram plotting. Then, Fn 
conformation was determined by pre-obtained calibration curves of FRET intensities as a 
function of chemically induced Fn denaturation as well as circular dichroism spectra of the 
denatured Fn, an indicator of Fn unfolding and β-sheet content, respectively (26). 
 
 
Analysis of ECM stiffness via Surface Forces Apparatus 
 
To measure the compressive elastic moduli of cell-free matrices deposited by ob/ob or 
wild-type ASCs, we used the Surface Forces Apparatus (SFA) (SurForce LLC) (27). For 
measurements, two mica surfaces (one holding the matrix) were mounted on a double 
cantilever of known spring constant (k = 980 N/m) and compressed with a bare mica 
surface from the top. The force acting between the surfaces was then measured as a function 
of surface separation (Fig. 3C). The two back-silvered, semicylindrical mica surfaces build 
an optical interferometer. For each pair, the bare (upper) surface used for indentation was 
kept in a desiccator until needed. The other (lower) surface was coated with 30 µg/ml of 
Fn (Invitrogen) in PBS, placed in a custom-made PDMS, and seeded with 2×104 wild-type 
or ob/ob ASCs. Following 24 hours of culture, matrices were decellularized (56). 
To measure their compressive Young’s modulus, paired discs were mounted in a 
crossed cylinder axis configuration, to obtain a well-defined flat circular junction 
equivalent to a sphere-on-flat like contact. The SFA chamber was filled with PBS at 37°C, 
keeping both discs fully immersed during the measurements. Individual samples were 
probed at four different positions approximately 0.5 mm apart. Each position was 
compressed at least 3 consecutive times with increasing normal force. 
Compressive measurements were performed in the quasi-static regime, at the 
lowest speed achievable with our normal motor (V = 8 to 9 nm/s) to prevent any viscous 
contribution. The system was allowed to equilibrate for 20 minutes between each 
compressive cycle. Measured force-distance profiles were further analyzed to extract the 
compressive elastic moduli using the Johnson contact mechanics model (57), in which the 
indentation under compression (d) between a sphere and a flat was related to normal force 
(F) by the following equation: 
𝐹	=	𝐸𝜋	𝛿
2
	
𝑅	 𝐷0	
	
where R is the equivalent radius of curvature of the cylindrical discs (R ~ 2 cm), D0 is the 
undistorted (prior to compression) thickness of the matrix, and E the compressive Young’s 
modulus of the ECM (Fig. 3C). 
 
 
Interstitial stiffness measurement by AFM 
 
AFM nanoindentation measurements were performed on 4-μm thick, rehydrated paraffin 
sections of wild-type and ob/ob mammary tissues using a MFP-3D-AFM scanning probe 
microscope (Asylum Research) mounted onto an Olympus IX-71 inverted optical 
microscope. Interstitial regions were probed using a 5-μm diameter borosilicate glass 
sphere attached to a silicon nitride cantilever (Novascan Tech). The nominal spring 
constant k (~0.06 N/m) of the cantilever was determined by thermal calibration prior to 
each measurement. AFM measurements were performed in contact mode under quasi- 
static conditions (V = 20 nm/s) in PBS. For the analysis, full force-indentation loading 
curves were recorded over small indentations (approximately 20 nm in depth) and, since 
no adhesion was measured, were fitted to the Hertz spherical indentation model; 
𝐹	=	
4	 3	𝐸√𝑅𝛿2	
3	
	
where F is applied force, R is the radius of the glass sphere (R ~ 5 μm), δ is indentation of 
tissue, and E is the Young’s modulus of the tissue. Analysis was performed using IGOR 
PRO software (WaveMetrics). The Young’s moduli (E) were calculated based on the 
resulting fit coefficients as the Poisson’s ratio was set to 0.5. Four samples with 20-30 
regions per sample were measured per condition (n = 4). 
 
 
Analysis of ASC responses to obesity-mediated ECM changes 
 
Decellularized matrices were used to study the impact of wild-type and ob/ob ECMs on 
ASC phenotype. Briefly, 3x104 wild-type or ob/ob ASCs were seeded on Fn-coated 
Thermanox coverslips (Thermo Scientific) and cultured for 8 days after which cells were 
removed through detergent-based extraction as previously described (56). Absence of 
cellular residuals was confirmed using DAPI staining (not shown) and Western blot 
analysis of GAPDH (fig. S9). The decellularized matrices were blocked with 1% BSA at 
4oC overnight prior to use. Subsequently, wild-type and ob/ob ASCs were cultured on the 
different decellularized ECMs in the presence and absence of Y-27632 (10 µg/ml) (Tocris) 
for 7 days. The number of α-SMA positive cells was assessed via IF image analysis as 
described above. Additionally, experiments were performed in which the matrices were 
pretreated with exogenous TGF-b (20 ng/ml) or anti-LAP (100 ng/ml) (both from R&D) 
at 37oC for an hour and washed twice with PBS prior to cell seeding. The quantity of 
matrix-bound TGF-b was measured by ELISA (R&D) of lysates from decellularized 
matrices. 
Analysis of tumor cell responses to obesity-mediated ECM changes 
 
To analyze ECM-induced variations in tumor cell behavior, MDA-MB231 and MCF10AT 
were cultured on the different decellularized matrices in low serum media (MDA-MB231: 
α-MEM, 1% FBS, 1% antibiotic; MCF10AT: DMEM/F12, 2% horse 
serum, 1% antibiotic) for 8 to 10 days (n = 3/condition). Cell growth was determined by 
counting trypsinized cells using a hemocytometer. Differences in FAK phosphorylation 
were determined by IF and Western blot analysis of pFAK[397], as described above. 
Tumor cell contractility was inhibited with Y27632 (10 µg/ml). To test potential effects of 
Fn conformational changes on MDA-MB231 growth, integrin engagement was inhibited 
with function-blocking αvβ3 (10 μg/ml) and/or α5β1 (10 μg/ml) integrin antibodies 
(Milllipore) prior to cell seeding and during the culture period. The role of wild-type and 
ob/ob ECMs in the disorganization of premalignant structures was determined by culturing 
MCF10AT acini on the different matrices in low serum media for 36 hours. To develop 
acini, MCF10AT (2,500 cells/well) were cultured in Lab-Tek chamber slides (Thermo 
Scientific) pre-coated with Matrigel (40 μl/well) (BD) for 10 days (35). Acini were isolated 
by multiple washes with ice-cold Tris-EDTA buffer (10 mM Tris buffer, 3 mM EDTA, and 
0.2% BSA) and subsequent short-centrifugation at 120 g, as described (35). Acini 
disorganization was assessed by confocal microscopy following IF for β-catenin (Abcam), 
β4 integrin (Millipore), Fn, and nuclei. Acini surface area and height were analyzed by 
confocal image analysis of Z-stacks (2-µm intervals) using Image J (n = 100 acini/group) 
(Fig. 5B). For MCF10AT migration analysis, decellularized wild-type and ob/ob matrices 
were prepared in glass bottom dishes (MetTek).  Matrices  were  fluorescently  labeled  by  
supplementing  the  respective ASC 
cultures with Alexa Fluor 488-labeled Fn for 2 days prior to decellularization; MCF10AT, 
cells were labeled with the membrane dye Dil Vybrant Cell-Labeling Solutions (Molecular 
Probes, Inc.). Time lapse imaging was initiated 5 hours after seeding using an inverted 
Andor/Olympus IX-83 spinning disk confocal microscope (Olympus Corporation, Tokyo, 
Japan). Z-stack images were captured at 8 different locations per sample every 5 mins, for 
5 hours. Cell motility was computed from the total distance of cell movement over time as 
measured with Image J. 
 
 
Tumor cell migration studies 
 
To investigate the effect of SDF-1 from ob/ob ASCs on tumor cell recruitment, a transwell 
migration assay was used. MDA-MB231 cells were seeded on collagen-coated transwell 
inserts (Corning Inc.), which were subsequently placed in wells that contained ASCs 
cultured in low serum media with or without SDF-1 antibody (50 µg/ml) (R&D). After 18 
hours, transwell membranes were fixed with formalin, stained with DAPI, and imaged from 
the bottom to the top with a Zeiss 710 confocal microscope. Subsequently, the number of 
migrated MDA-MB231 cells was quantified via manual counting of DAPI- stained nuclei 
at the bottom of the membrane. To further confirm the importance of the SDF-1/CXCR4 
signaling axis to varied MDA-MB231 migration, SDF-1 signaling was inhibited by 
blocking its corresponding receptor with a CXCR-4 antibody (25 µg/ml) (R&D) (n = 
3/group). 
 
 
Analysis of tumor-free human breast tissues 
A previously published set of 29 tumor-free, human breast tissues categorized into normal, 
overweight and obese was used to assess the effect of obesity on interstitial fibrosis in 
humans (37). Specimens were collected from patients undergoing mastectomy whereby 
samples were harvested from either the contralateral breast or from quadrants not involved 
by the tumor to ensure that tumor-free tissue was analyzed. Paraffin sections were used for 
the analysis of collagen fiber structure by SHG imaging as well as levels of α-SMA positive 
cells. Furthermore, snap frozen tissue was used to analyze levels of TGF-β mRNA. Total 
RNA was isolated and processed as described previously (37). The forward and reverse 
primers for TGF-β were 5'-GAGCCTGAGGCCGACTACTA-3' and 5'-
CGGAGCTCTGATGTGTTGAA-3'; and for GAPDH 5'- 
TTCTTTTGCGTCGCCAGCCGA-3' and 5'-GTGACCAGGCGCCCAATACGA-3'. 
Real-time PCR was conducted using 2x SYBR green PCR master mix on a 7500 HT real- 
time PCR system (Applied Biosystems), with expression determined using the DDCT 
analysis protocol. The quantity of crown-like structures in each breast sample (CLS-B) was 
determined as previously described and indicated as CLS-B index (37). 
 
 
Analysis of patient-derived breast tumor specimens 
 
Paraffin-embedded breast tumor specimens were obtained from existing archived  samples 
of 17 lean and 18 obese breast cancer patients under the approval of IRB Study 0408007390 
at Weill Cornell Medical College. Tumor specimens were categorized by the patient’s body 
mass index (BMI = mass [kg]/(height [m])2) whereby a BMI of < 25 and > 30 was 
considered lean and obese, respectively. The two cohorts were evenly matched  for age, 
menopausal status, as well as subtype of breast cancer (table S1). In both groups, 
the majority of patients (83%) had stage 3 breast cancer at diagnosis and the remainder 
(17%) had de novo stage IV breast cancer as their initial diagnosis. To assess the degree of 
desmoplasia, H&E-stained sections were scored by a pathologist in a blinded manner. 
Additionally, specimens were subjected to SHG image analysis of collagen as well as IF 
staining of a-SMA, Fn, and YAP/TAZ (clone sc101199; Santa Cruz) as described above. 
For the latter, images of 10 randomly selected areas of the whole tumor were captured per 
sample and subjected to image analysis; YAP/TAZ analysis was done on epithelial regions 
of the tumors as determined morphologically. 
 
 
Gene ontology data analysis 
 
To test the clinical link between obesity-mediated transcriptomic changes of ECM, cell 
adhesion, and inflammation, gene ontology analysis was performed based on previously 
published data of estrogen receptor (ER)+ breast cancer patients (39). A list of the most 
significantly differentially expressed genes across lean vs. obese patients was analyzed to 
identify enrichment for ECM-, adhesion-, and inflammation-related gene signatures. 
Pathway analysis was performed on the differentially expressed genes using the tool 
DAVID (58) to reveal enrichment for various known functional pathways. Favorable 
functional pathways were then selected based on significance (P < 0.05) and false- positive 
rate (Benjamini; FDR < 0.2). A co-expression analysis was performed using R statistical 
software to correlate the identified ECM-, inflammation-, and YAP/TAZ- related genes. 
Affymetrix gene expression values were evaluated to obtain expression- based correlations, 
and significantly co-expressed genes (P < 0.05) were selected based on adjusted P value 
(FDR < 0.2). 
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Fig. S1: Obesity promotes interstitial fibrosis in breast adipose tissue after 
menopause. (A) Ovariectomized (OVX) mice subjected to a high-fat diet (HFD) for 10 
weeks were used as a postmenopausal obesity model; age-matched OVX mice fed a low- 
fat diet (LFD) served as controls. (B and C) IF analysis of a-SMA (B) and fibronectin (Fn) 
(C) content in mammary fat from OVX mice. Scale bars, 200 μm. Data are means ± SD (n 
= 5 to 6/group). P values determined by unpaired Student’s two-tailed t-tests. 
 
 
 
Fig. S2. Inguinal depots of adipose tissue feature markers of interstitial fibrosis (A, B) 
Western blot analysis of α-SMA (A) and fibronectin (Fn) (B) levels in inguinal adipose 
tissue (a mix of s.c. and mammary fat) from ob/ob or wild-type (WT) mice. Data indicate 
average α-SMA or Fn intensity relative to HSP90 intensity with ± SD (n = 3/condition). P 
values were determined by unpaired two-tailed t-tests. NS, not significant. 
(C) IF analysis of α-SMA and Fn levels of ob/ob ASCs from inguinal and mammary fat. 
Scale bars, 100 μm. 
 
 
Fig. S3: The profibrotic potential of ob/ob ASCs is not due to leptin deficiency. (A 
and B) IF analysis of α-SMA expression (A) and fibronectin (Fn) levels (B) of ASCs with 
and without leptin supplementation. Data are means ± SD (n = 3/group). *P < 0.05, **P 
< 0.01, by two-way analysis of variance (ANOVA). 
 
 
Fig. S4: Obesity-associated ASCs promote fibrotic ECM remodeling in visceral fat. 
(A and B) IF analysis of α-SMA (A) and fibronectin (Fn) (B) of ASCs isolated from 
visceral fat. Data are means ± SD (n = 3/condition). (C) FRET analysis of Fn conformation 
in the matrices deposited by ASCs from visceral depots. (Left) Pseudocolored Fn matrices; 
box and whiskers plots of FRET intensity of 6-8 representative fields of view per condition. 
(Right) Histograms of the corresponding distributions of FRET intensity (n = 4-
5/condition). P values in (A to C) were determined by unpaired two-tailed t-tests. (D) 
Confocal analysis of matrix thickness. Data are means 
± SD (n = 10-15/condition). P values were determined by one-way ANOVA. All scale 
bars, 200 μm. 
 
 
Fig. S5: ECMs deposited by obesity-associated ASCs promote myofibroblast 
differentiation (A) Schematic illustrates that matrices deposited by WT and ob/ob ASCs 
(WT and ob/ob ECM, respectively) were decellularized and reseeded with either WT or 
ob/ob ASCs to examine their effect on ASC myofibroblast differentiation. (B) IF analysis 
of α-SMA levels in WT and ob/ob ASCs cultured on ob/ob or WT ECMs, in the presence 
or absence of Y27632. Scale bars, 50 μm. (black asterisk) *P < 0.05 versus WT-ASCs 
cultured on ob/ob ECM; (blue asterisk) *P < 0.05 versus ob/ob ASCs cultured on WT 
ECM; (red asterisk) *P < 0.05 versus ob/ob ASCs cultured on ob/ob ECM; two-way 
ANOVA. (C) ELISA of matrix-bound TGF-β in lysates prepared from decellularized WT 
and ob/ob matrices. NS, not significant, by unpaired two-tailed t-test. (D) The impact of 
TGF-β on phenotypic changes of ASCs was analyzed by saturating decellularized matrices 
with exogenous TGF-β prior to cell seeding and by blocking TGF-β activation using a LAP 
antibody. Scale bars, 50 μm. (black asterisk) *P < 0.05 versus WT-ASCs cultured on WT 
ECM; (red asterisk) *P < 0.05 versus WT-ASCs cultured on WT ECM with a LAP 
antibody; two-way ANOVA. Data in (B to D) are means ± SD (n = 3/condition). 
 
 
Fig. S6: Physicochemical cues of ob/ob ECMs modulate MDA-MB231 behavior. (A) 
Analysis of MDA-MB231 growth on WT and ob/ob ECMs in the presence and absence of 
a5b1 and avb3 function-blocking antibodies. (B) IF analysis of pFAK levels in MDA- MB231 
cultured on the different decellularized ECMs in the presence and absence of Y27632. *P 
< 0.05 versus WT with Y27632, ***P < 0.001 versus all other groups. Scale bars, 50 μm. 
(C) Transwell migration assays of MDA-MB231 in response to SDF-1 secreted by ob/ob 
or WT ASCs. SDF-1–dependent migration of MDA-MB231 cells was assessed by 
antibody-based inhibition of both ASC-secreted SDF-1 and the tumor cells’ cognate 
CXCR4 receptor. *P < 0.05 versus all other groups. In (A to C), data are means 
± SD (n = 3/condition), and P values were determined by two-way ANOVA. 
 
 
Fig. S7: H&E images of breast tumors with different subtypes. Representative H&E 
images of different tumor subtypes used in this study. Luminal A tumors are shown in Fig. 
7A. All scale bars, 200 μm. 
 
 
Fig. S8: Caloric restriction decreases fibrosis in mammary fat of obese mice. (A) 
Schematic showing the experimental design for caloric restriction experiments: 
ovariectomized mice (OVX) were fed with HFD for 10 weeks with and without 30% of 
caloric restriction for 7 weeks. (B and C) Western blot analysis of α-SMA (B) and 
fibronectin (Fn) (C) content in excised mammary fat from mice on LFD or HFD with or 
without caloric restriction (CR). Data are means ± SD (n = 5 to 6/group). P values were 
determined by one-way ANOVA. NS, not significant. 
 
 
 
 
 
 
 
 
 
Fig. S9: Decellularized ECMs do not contain cellular residuals. GAPDH WB analysis 
of lysates prepared from ob/ob ASC cultures prior to (Cell +) and following (Cell -) 
decellularization to confirm that decellularized matrices did not contain cell-associated 
residuals. 
Table S1: Subtypes, demographics, and desmoplastic grade of lean and obese breast 
cancer samples. Statistical examination of clinical specimens from 17 lean and 18 obese 
breast cancer patients to confirm parity of age, cancer subtype, and menopausal status 
between the two cohorts. Histopathological analysis was performed to determine the 
desmoplastic grade of the tumor specimens. Grades 1, 2 and 3 indicate mild, moderate, and 
severe desmoplasia, respectively. P values were determined by Fisher’s exact test. 
 
Cancer subtype Classification criteria 
Luminal (HER2 status not specified) ER+ and/or PR+, and HER2+/− 
Luminal A ER+ and/or PR+, HER2−, and low Ki67 (<14%) 
Luminal B ER+ and/or PR+, HER2−, and high Ki67 (>14%) 
Luminal A/B ER+ and/or PR+, HER2−, and no Ki67 available 
Luminal HER2 ER+ and/or PR+, and HER2+ 
HER2/neu enriched ER−, PR−, and HER2+ 
Triple negative ER−, PR−, and HER2− 
Basal-like ER−, PR−, HER2−, and CK5/6 and/or EGFR+ 
 
 
Variable 
 Body type  
P- value Lean 
(n = 17) 
Obese 
(n = 18) 
 
 
 
Age 
< 30 1 0  
 
 
1 
30 ≤ age < 40 6 6 
40 ≤ age < 50 3 3 
50  ≤ age 7 9 
Median age 43 43 
 
 
 
 
 
 
Cancer type 
Luminal 
(HER2 status not specified) 
4 (23.5%) 4 (22.2%)  
 
 
 
 
 
0.782 
Luminal A 1 (5.9%) 3 (16.7%) 
Luminal B 3 (17.7% 2 (11.1%) 
Luminal A/B 4 (23.5%) 2 (11.1%) 
Luminal HER2 2 (11.8%) 3 (16.7%) 
HER2/neu enriched 1 (5.9%) 0 
HER2 negative 0 1 (5.6%) 
ER/PR negative 1 (5.9%) 0 
Triple negative 1 (5.9%) 1 (5.6%) 
 Basal-like 0 2 (11.1%)  
 
Menopausal status 
Pre-menopausal 10 (58.8%) 10 (55.6%)  
1 
Post-menopausal 7 (41.2%) 8 (44.4%) 
 
Desmoplastic 
grade 
Grade 1 6 (35.3%) 0  
0.006 Grade 2 9 (52.9%) 8 (44.4%) 
Grade 3 2 (11.8%) 10 (55.6%) 
Table S2. Gene ontology data analysis. Bioinformatics analysis of published data to test 
whether obesity enriches functional pathways associated with ECM-, adhesion-, and 
inflammation-related gene signatures in estrogen receptor–positive breast cancer patients. 
 
Category Term P-value Benjamini (FDR) 
ECM related gene sets 
SP_PIR_KEYWORDS Secreted 2.67E-15 7.30E-13 
SP_PIR_KEYWORDS Signal 6.84E-13 9.38E-11 
UP_SEQ_FEATURE Signal peptide 8.76E-13 4.46E-10 
GOTERM_CC_FAT GO:0005576~extracellular region 9.75E-12 1.76E-09 
GOTERM_CC_FAT GO:0044421~extracellular region part 4.96E-11 4.47E-09 
GOTERM_CC_FAT GO:0005615~extracellular space 6.06E-11 3.64E-09 
UP_SEQ_FEATURE Disulfide bond 6.49E-09 1.65E-06 
SP_PIR_KEYWORDS Disulfide bond 1.55E-08 1.42E-06 
SP_PIR_KEYWORDS Glycoprotein 6.21E-07 4.26E-05 
Cell adhesion related gene sets 
SP_PIR_KEYWORDS Cell adhesion 0.009 0.097 
Inflammation related gene sets 
GOTERM_BP_ALL GO:0050727~regulation of 
inflammatory response 
0.002 0.055 
GOTERM_BP_FAT GO:0050727~regulation of 
inflammatory response 
0.002 0.109 
GOTERM_BP_ALL GO:0006954~inflammatory response 0.007 0.132 
Table S3: Correlation of YAP/TAZ-regulated genes with obesity-dependent ECM 
remodeling/inflammation. Bioinformatics analysis of published data from obese ER+ 
breast cancer patients (39) to test whether some of the eight obesity- induced genes that 
are common to both ECM- and inflammation-related pathways correlate with the 
YAP/TAZ-regulated genes CTGF and ANKRD1. 
 
Inflammation 
-ECM gene 
probe ID 
NCBI 
gene 
name 
Description Correlation P-value Adjusted 
P-value 
(FDR) 
YAP/TAZ related gene ANKRD1 
202859_x_at IL8 Interleukin 8 0.18 7.45E-06 1.79E-05 
203400_s_at TF Transferrin 0.16 2.58E-05 5.15E-05 
205382_s_ CFD Complement factor D 
(adipsin) 
-0.08 0.043 0.057 
207175_at ADIPOQ Adiponectin, C1Q and 
collagen 
domain containing 
0.11 0.007 0.011 
207400_at NPY5R Neuropeptide Y receptor 
Y5 
0.35 0 0 
211506_s_at IL8 Interleukin 8 0.12 0.002 0.004 
211652_s_at LBP Lipopolysaccharide 
binding 
protein 
0.36 0 0 
214063_s_at TF Transferrin 0.22 3.02E-08 1.21E-07 
214461_at LBP Lipopolysaccharide 
binding 
protein 
0.19 2.77E-06 8.32E-06 
YAP/TAZ related gene CTGF 
203400_s_at TF Transferrin 0.086 0.032 0.13 
207175_at ADIPOQ Adiponectin, C1Q and 
collagen 
domain containing 
0.088 0.028 0.13 
203400_s_at TF Transferrin 0.12 0.003 0.035 
 
